Conavi Medical Advances Hybrid Intravascular Imaging Platform as Revenue Jumps in Fiscal 2025

An update from Conavi Medical ( (TSE:CNVI) ) is now available.

Conavi Medical reported that fiscal 2025 marked a pivotal year, highlighted by the U.S. FDA 510(k) submission of its next-generation Novasight Hybrid™ IVUS/OCT coronary imaging system, strengthened balance sheet via a $20 million equity financing led by U.S. institutional investors, and eligibility for up to $2.5 million in non-dilutive funding from Ontario’s Life Sciences Scale-Up Fund. The company advanced manufacturing and operational readiness for an anticipated U.S. commercial launch, capitalized on growing clinical guideline support in the U.S. and Europe for intravascular imaging in complex PCI, and saw revenue rise to $9.1 million from $2.2 million, largely from licensing and milestone payments in China and limited first-generation product sales, reinforcing its bid to secure a differentiated position as a hybrid IVUS/OCT leader in a rapidly expanding market.

The most recent analyst rating on (TSE:CNVI) stock is a Buy with a C$1.00 price target. To see the full list of analyst forecasts on Conavi Medical stock, see the TSE:CNVI Stock Forecast page.

More about Conavi Medical

Conavi Medical Corp. is a Toronto-based commercial-stage medical device company that designs, manufactures and markets intravascular imaging technologies to guide minimally invasive cardiovascular procedures. Its flagship product line is the Novasight Hybrid™ system, a dual-modality IVUS/OCT platform aimed at image-guided percutaneous coronary interventions (PCI), with a strategic focus on the U.S., European and Asian interventional cardiology markets.

YTD Price Performance: -31.43%

Average Trading Volume: 22,198

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$25.65M

For detailed information about CNVI stock, go to TipRanks’ Stock Analysis page.